Cure8 research brief
This review summarizes large-scale real-world evidence on JAK inhibitors for UC and CD, which can help patients and clinicians understand how these drugs perform outside of clinical trials and what safety outcomes have been observed in routine practice.
Adult IBD patients (UC and CD), clinicians treating IBD, researchers studying IBD therapies, and patients considering or currently on JAK inhibitors.
This paper is a systematic review and meta-analysis of real-world studies evaluating JAK inhibitors (tofacitinib, upadacitinib, filgotinib) in inflammatory bowel disease.
The authors pooled outcomes from 63 studies including 8,130 IBD patients and report pooled clinical response and remission rates for UC and CD, plus safety outcomes such as hospitalization, treatment discontinuation, and serious adverse events.
The review finds that all three JAK inhibitors produced clinically meaningful rates of response and remission in ulcerative colitis and that upadacitinib also showed substantial effectiveness in Crohn’s disease.
Reported safety signals in these real-world cohorts were generally low: no drug-related mortality was observed, serious adverse events were ≤8% across agents, and discontinuation/hospitalization rates varied by drug.
If you are taking or considering a JAK inhibitor, this study adds broader, real-world outcome data beyond clinical trials, but it does not replace individualized medical advice. Discuss any treatment decisions, potential risks, and monitoring plans with your gastroenterology team.
Structured content depth is abstract: the brief is grounded in the source-provided abstract and not a full independent review of the full paper. Real-world studies vary in design and quality; pooled observational data can be influenced by selection bias, differing outcome definitions, and variable follow-up.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
The review compiles trial and real-world safety data for upadacitinib in IBD and highlights monitoring needs and infection risks (notably herpes zoster), which are directly relevant when choosing or managing JAK...
